Innovent Biologics Inc Cash Flow Conversion Efficiency
Innovent Biologics Inc cash flow conversion efficiency. Based on the latest financial reports, Innovent Biologics Inc (6IB) has a cash flow conversion efficiency ratio of -0.029x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-311.45 Million ≈ $-364.11 Million USD) by net assets (€10.78 Billion ≈ $12.61 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Innovent Biologics Inc (2016–2025)
Cash flow conversion efficiency of Innovent Biologics Inc from 2016 to 2025. This chart illustrates how Innovent Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Innovent Biologics Inc (6IB) stock price for real-time trading data and today's change.
Innovent Biologics Inc Cash Flow Conversion Ratio Explained
Innovent Biologics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Innovent Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innovent Biologics Inc ranked by their cash flow conversion efficiency. Also see Innovent Biologics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OMV AG ADR 1
F:OMVI
|
0.036x |
|
Suncorp Group Ltd
AU:SUNPH
|
-0.042x |
|
SAIC Motor Corp Ltd
SHG:600104
|
0.041x |
|
Kasikornbank Public Company Limited
BK:KBANK
|
0.054x |
|
ITT Inc
NYSE:ITT
|
0.008x |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
0.028x |
|
China Minsheng Banking Corp Ltd
SHG:600016
|
0.014x |
|
Bank of Hangzhou Co Ltd
SHG:600926
|
0.013x |
Annual Cash Flow Conversion Efficiency for Innovent Biologics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Innovent Biologics Inc from 2016 to 2025. Review how much free cash does Innovent Biologics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €19.36 Billion ≈ $22.63 Billion |
€10.00 Billion ≈ $11.69 Billion |
0.517x | +426.62% |
| 2024-12-31 | €13.12 Billion ≈ $15.34 Billion |
€1.29 Billion ≈ $1.50 Billion |
0.098x | +731.56% |
| 2023-12-31 | €12.53 Billion ≈ $14.65 Billion |
€147.81 Million ≈ $172.81 Million |
0.012x | +106.60% |
| 2022-12-31 | €10.73 Billion ≈ $12.54 Billion |
€-1.92 Billion ≈ $-2.24 Billion |
-0.179x | +8.77% |
| 2021-12-31 | €10.33 Billion ≈ $12.08 Billion |
€-2.02 Billion ≈ $-2.37 Billion |
-0.196x | -459.30% |
| 2020-12-31 | €8.78 Billion ≈ $10.26 Billion |
€-307.69 Million ≈ $-359.72 Million |
-0.035x | +89.99% |
| 2019-12-31 | €4.76 Billion ≈ $5.56 Billion |
€-1.66 Billion ≈ $-1.95 Billion |
-0.350x | -45.07% |
| 2018-12-31 | €4.19 Billion ≈ $4.90 Billion |
€-1.01 Billion ≈ $-1.18 Billion |
-0.241x | -179.49% |
| 2017-12-31 | €-1.62 Billion ≈ $-1.90 Billion |
€-492.27 Million ≈ $-575.52 Million |
0.303x | -19.89% |
| 2016-12-31 | €-958.22 Million ≈ $-1.12 Billion |
€-362.99 Million ≈ $-424.38 Million |
0.379x | -- |
About Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, a… Read more